Revvity Signals || Signals One™

EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Advertise Smarter with the 2025 Pharma Focus Europe Media Pack

    The internet has forever changed the healthcare industry and it is no longer whether to advertise but how to advertise better in the changing digital world Following the shift of pharma marketing to precision personalization and performance Pharma Focus Europe Media Pack is precisely your prescription to be the best in terms of competing in the European market

    Chiral Biosensors: Precision Tools for Safer Drugs

    The pharmaceutical industry has long been recognised the profound implications of chirality in drug design and development Enantiomers mirrorimage isomers of a chiral molecule show dramatically distinct pharmacokinetic PK and pharmacodynamic PD profiles One may be therapeutically active while its counterpart could be inactive or harmful As a result the precise detection discrimination and quantifi...

    Single-Use Technologies: Accelerating Flexible Biopharmaceutical Manufacturing

    For most of the past two decades the case for singleuse technologies in biopharmaceutical manufacturing was argued in the language of the plant Disposable bags and flow paths removed cleaninplace and steaminplace loops shortened turnarounds and allowed engineers to stand up a suite without a validation campaign measured in seasons That argument has been won Disposable systems now appear at every s...

    Pharma Email Marketing Europe: Personalized Campaigns for C-Suite Leads

    The pharmaceutical industry is a very competitive industry and to reach the decisionmakers a focused and strategic marketing strategy is necessary Conventional marketing is not often precise enough to reach executives that drive buying alliances and strategic relationships Here the pharma email marketing has come to play as a potent instrument of relationship establishment with the key stakeholder...

    What is Clinical Drug Trials and what are the four phases of clinical trials

    In a clinical trial actors admit specific interventions according to the exploration plan or protocol created by the investigators These interventions may be medical products similar as medicines or bias procedures or changes to actors geste similar as diet Clinical trials may compare a new medical approach to a standard bone thats formerly available to a placebo that contains

    Brain Delivery of Biologics with Trojan Horse Shuttles: Remembering Paracelsus

    Paracelsus in the th century established the principle of toxicology that the dose of a medicinal defines the difference between a remedy and a toxic effect

TOP ARTICLES

  • 1

    Chiral Biosensors: Precision Tools for Safer Drugs

    Dr. Selvakumar Kanthiah

    Dr. Valliappan Kannappan

    In drug development, identifying the right mirror-image molecule - called an enantiomer - can be the difference between a life-saving treatment and unwanted side effects. Chiral biosensors are revolut...

press releases Read more...

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

MacroGenics Inc a clinicalstage biopharmaceutical company focused on developing innovative antibodybased therapeutics for the treatment of cancer today announced that the first patient has been dosed in the Phase study of MGC a firstinclass antibodydrug conjugate

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

Legend Biotech Corporation a global leader in cell therapy today announced that the US Food and Drug Administration FDA has cleared the investigational new drug IND application for LB an investigational in vivo CART therapy designed to generate CDCD dualtargeting chimeric antigen receptor T

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Eikon Therapeutics Inc a latestage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs today announced the submission of an Investigational New Drug IND application to the US Food and Drug Administration FDA to evaluate EIK for the t...

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome

Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWS Read more...

AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials

AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support

Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments

Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments

Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Insitro an AI company unlocking causal human biology to systematically generate highvalue therapeutics to treat grievous illness today announced a worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunctionassociated steat...

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize

Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial

Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics